Newsroom
Media ContactIlana Ostrin, Senior Director of Public Relations & CommunicationsTime sensitive requests: 212-328-3769 (call or text)Non-urgent requests: iostrin@hemophilia.org About NBDFFor nearly 75 years, The National Bleeding Disorders…
Annual Bleeding Disorders Conference Returns in Virtual Form this August
FOR IMMEDIATE RELEASE MEDIA CONTACT: Ilana Ostrin 212-328-3769 iostrin@hemophilia.org August 23, 2021 — New York City —The annual Bleeding Disorders Conference (BDC),…
Gene Therapy for Inheritable Bleeding Disorders
Gene Therapy for Inheritable Bleeding Disorders Speaker: Valder R. Arruda. MD, PhD - Children's Hospital of Philadelphia NHF's Wednesday Webinars are a free education series open to providers and community…
Vector Biology and Hemophilia Gene Therapy the Focus of Review
A new review article, “The Intersection of Vector Biology, Gene Therapy, and Hemophilia,” was published recently in the journal Research Practice in Thrombosis & Haemostasis (RPTH). It provides a comprehensive overview of the scientific…
NHF and HFA Unite in New Partnership
September 7, 2021  FOR IMMEDIATE RELEASE  Media Contacts Ilana Ostrin, National Hemophilia Foundation iostrin@hemophilia.org 212-328-3769  Meghan Lawton, Hemophilia Federation of America…
NHF Responds to STIMATE® Production Update
CSL Behring announced that the company’s distribution agreement with Ferring Pharmaceuticals for STIMATE® nasal spray recently expired and will not be renewed effectively removing this medication as a valuable treatment option for patients with von…
NHF’s State Advocacy and the Bleeding Disorders Community
Objective: NHF Chapters must develop, support, and sustain influential advocacy programs to protect and enhance access to health care for the bleeding disorders community. Method: NHF supports the…
First-ever State of the Science Research Summit Begins
FOR IMMEDIATE RELEASE MEDIA CONTACT: Ilana Ostrin 212-328-3769 iostrin@hemophilia.org September 12, 2021 — New York City —The State of the Science Research Summit (SOS),…
Prophylaxis Indication Restored for BeneFIX®
In February 2021, the U.S. Food and Drug Administration (FDA) partially rescinded a supplemental Biologics License Application (BLA) that the agency had granted, in error, for the recombinant factor IX product BeneFIX® (Pfizer). The temporary…
Developing My Bleeding Disorders Community (MyBDC): A community-powered registry to provide a 360-view of living with a bleeding disorder
Knowing the importance of including the consumers voice in the future of research, the National Hemophilia Foundation (NHF) partnered with the software healthcare analytics company; ArborMetrix, to develop a cloud-based platform; NHF’s Community…